The REDDS-2 Study
A trial to assess a novel transfusion schedule in patients with myelodysplastic syndromes
About REDDS-2
Building on the success of the REDDS-1 Trial, a feasibility trial which investigated haemoglobin concentration transfusion thresholds in patients with myelodysplastic syndromes (MDS), the REDDS-2 Study is a randomised clinical trial that will assess the feasibility of a weekly red cell transfusion schedule (using matched red cells) and its impact on quality of life and physical function outcomes in patients with transfusion-dependent MDS.
A collaboration between Australia, the UK and the Netherlands, the aim of this study is to inform the design and conduct of a definitive international randomised trial to compare different strategies for red blood cell transfusion in outpatients with MDS.
-
What does the study involve?
Our research team will assess a novel weekly transfusion schedule, using matched red cells, in patients with transfusion-dependent myelodysplastic syndromes (MDS).
-
Participating hospitals
The REDDS-2 Study is currently being piloted in hospitals in Australia, the UK and the Netherlands.
-
Meet the team
This Study is a collaboration between researchers from Monash University, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Radboud University Medical Center, and hospitals in Australia, the UK and the Netherlands.
Latest news
-
First site opens for recruitment in Australia
Monash Health, Clayton is the lead Australian Site for the REDDS-2 Study. In December 2019, Monash Health was the first of three sites in Australia to open for recruitment.
-
The REDDS-2 Study receives ethics approval
The REDDS-2 Study received Human Research Ethics Approval in Australia from Monash Health Human Research Ethics Committee. Monash Health is the lead site in Australia.
Contact us
For further information about REDDS-2 or if you would like to be involved in the Study: